PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results
• Over 50% of planned 60 centers for ongoing Phase 3 SHIELD I trial of D-PLEX100 in abdominal surgery have received IRB approval • Phase 3 SHIELD II trial advanced; preparations underway to initiate by year-end 2020 • Conference Call Scheduled for …